Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 1999

View Archived Issues

Nycomed Amersham: 1999 half-year highlights include first mention of new product

Evacet/Taxotere combination therapy to be assessed in metastatic breast cancer

Endovasc reaches liposomal VEGF development agreement with Hermes Biosciences

Biomira's BLP25 cancer vaccine tested at higher dose and frequency

Orion: 5 NDAs under review in H1 1999

Gliadel Wafer approved in Germany for recurrent GBM

PolyMASC announces factor VIII research agreement with Bayer

CAT and HGS enter agreement for therapeutic antibody development

Centaur conducts phase IIa trials on two product candidates in Q2 1999

Melatonin antagonist S-22153 blocks phase-advancing effects of melatonin in vivo in mice

Oxigene licenses combretastatin prodrug from Arizona State University

Isotechnika advances development of new immunosuppressant

Texas Biotechnology highlights key developments for first half of 1999

Cordox shows cardioprotective effect during prolonged ischemia

Clot buster eptifibatide now on the market in U.K.

Neuronal calcium channel-modulating compounds from Lilly useful in treating CNS disorders

Potential new flu drugs described by BioCryst

Pfizer reveals new series of nicotinic acetylcholine receptor-modulating agents

Bayer research into metabotropic glutamate receptor ligands proves fruitful

K-252a derivatives with potential application in cancer and neurologic disorders

Quidel acquires Metra Biosystems, expands product line

Novel antibiotic series described in patent literature by HMR

COX-2 inhibitor research continues at Searle

STA-BX909: a promising new agent for BNCT

SunPharm to merge with GelTex

FDA approves Chiroscience's injectable anesthetic

Licensing opportunity from BTG: novel compounds for treating MRSA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...